Path ID: DB00926_MESH_D011565_1
Concepts
| Identifier | Name | Type |
|---|---|---|
| MESH:D005050 | Etretinate | Drug |
| UniProt:P10276 | Retinoic acid receptor alpha | Protein |
| UniProt:P10826 | Retinoic acid receptor beta | Protein |
| UniProt:P19793 | Retinoic acid receptor RXR-alpha | Protein |
| UniProt:P48443 | Retinoic acid receptor RXR-gamma | Protein |
| GO:0031424 | Keratinization | BiologicalProcess |
| GO:0010481 | Epidermal cell division | BiologicalProcess |
| MESH:D011565 | Psoriasis | Disease |
Relationships
NOTE: predicates are annotated in Biolink Model (v1.3.0)
| Subject | Predicate | Object |
|---|---|---|
| Etretinate | INCREASES ACTIVITY OF | Retinoic Acid Receptor Alpha |
| Etretinate | INCREASES ACTIVITY OF | Retinoic Acid Receptor Beta |
| Etretinate | INCREASES ACTIVITY OF | Retinoic Acid Receptor Rxr-Alpha |
| Etretinate | INCREASES ACTIVITY OF | Retinoic Acid Receptor Rxr-Gamma |
| Retinoic Acid Receptor Alpha | NEGATIVELY REGULATES | Keratinization |
| Retinoic Acid Receptor Rxr-Alpha | NEGATIVELY REGULATES | Keratinization |
| Retinoic Acid Receptor Beta | NEGATIVELY REGULATES | Keratinization |
| Retinoic Acid Receptor Rxr-Gamma | NEGATIVELY REGULATES | Keratinization |
| Retinoic Acid Receptor Alpha | NEGATIVELY REGULATES | Epidermal Cell Division |
| Retinoic Acid Receptor Rxr-Alpha | NEGATIVELY REGULATES | Epidermal Cell Division |
| Retinoic Acid Receptor Beta | NEGATIVELY REGULATES | Epidermal Cell Division |
| Retinoic Acid Receptor Rxr-Gamma | NEGATIVELY REGULATES | Epidermal Cell Division |
| Keratinization | POSITIVELY CORRELATED WITH | Psoriasis |
| Epidermal Cell Division | POSITIVELY CORRELATED WITH | Psoriasis |
Comment: Withdrawn. Etretinate was taken off the market in Canada in 1996 and America in 1998 due to the risk of birth defects. Etretinate is now used to treat T-cell lymphomas.
Reference: